Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer

Expert Opinion on Investigational Drugs

Volumn 23, Issue 10, 2014, Pages 1333-1348

  Lee, Chieh Chien ^a   Shiao, Hui Yi ^a   Wang, Wen Chieh ^a   Hsieh, Hsing Pang ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Afatinib; AZD 9291; CO 1686; Dacomitinib; EGFR; Erlotinib; Gefitinib; Icotinib; NSCLC

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFATINIB; AL 6802; AZD 9291; CANERTINIB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HM 61713; ICOTINIB; JNJ 26483327; KD 019; LAPATINIB; N [3 [[5 CHLORO 2 [[2 METHOXY 4 (4 METHYL 1 PIPERAZINYL)PHENYL]AMINO] 4 PYRIMIDINYL]OXY]PHENYL]ACRYLAMIDE; NERATINIB; PELITINIB; POZIOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; ROCILETINIB; TAK 285; TANTALUM; TAS 2913; UNCLASSIFIED DRUG; VARLITINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

BINDING AFFINITY; BLADDER CANCER; BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CRYSTAL STRUCTURE; GENE MUTATION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; MONOTHERAPY; NASOPHARYNX CARCINOMA; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SKIN CARCINOMA; SMALL CELL LUNG CANCER; SURVIVAL RATE; SURVIVAL TIME; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG RESISTANCE; GENETICS; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84907049059     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.928283     Document Type: Review

References (117)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
2. Hodkinson PS, MacKinnon A, Sethi T. Targeting growth factors in lung cancer. CHEST J 2008;133:1209-16
3. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-58
4. Oxnard GR, Jänne PA. KRAS wild-type lung cancer: a moving target in an era of genotype migration. J Clin Oncol 2012;30:3322-4
5. Lee JK, Park HS, Kim D-W, et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer 2012;118:3579-86
6. Sequist LV, Lynch TJ. EGFR Tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med 2008;59:429-42
7. Nyati MK, Morgan MA, Feng FY, et al. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006;6:876-85
8. Chen YM. Clinical application of epidermal growth factor receptor tyrosine kinase inhibitors against NSCLC. J Cancer Mol 2005;1:83-91
9. AstraZeneca secures first market approval for Iressa in Japan. Available from: http://www.astrazeneca.com/Media/ Press-releases/Article/20020705-ASTRAZENECA-SECURES-FIRSTMARKET-APPROVAL-FOR-IRESSA [Last accessed 17 April 2014]
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
11. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
12. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11
13. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-46
14. Carey KD, Garton AJ, Romero MS, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66:8163-71
15. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58
16. FDA Public Health Advisory. New labeling and distribution program for gefitinib (Iressa). FDA/Center for Drug Evaluation and Research, Washington, DC; 2009. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor PatientsandProviders/ucm163112.htm [Last accessed 20 December 2013]
17. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 2006;107:1207-18
18. Nishimura T, Tada H, Nakagawa M, et al. Lessons from gefitinib-induced interstitial lung disease in Japan: problems in approval, pharmacovigilance, and regulatory decision-making procedures. Pharm Pract (Granada) 2006;4:168-78
19. Ministry of Health, Labour and Welfare. An opinion on evaluation of the results of ISEL study and future countermeasures for the use of Iressa. Available from: http://www.mhlw.go.jp/ shingi/2005/03/s0324-12.html [Last accessed 12 May 2014]
20. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37
21. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84
22. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94
23. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 2009;361:947-57
24. Passaro A, Gori B, de Marinis F. Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials. J Thorac Dis 2013;5:383-4
25. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-8
26. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8
27. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
28. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
29. Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by secondline cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 2012;30:3002-11
30. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 2007;25:1545-52
31. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9
32. Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42
33. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46
34. Erlotinib. 2013. Available from: http://www.fda.gov/drugs/ informationondrugs/approveddrugs/ ucm352317.htm [Last accessed 23 December 2013]
35. A study of onartuzumab (MetMAb) in combination with tarceva (erlotinib) in patients with met diagnostic-positive non-small cell lung cancer who have received chemotherapy for advanced or metastatic disease. Available from: http:// clinicaltrials.gov/show/NCT01456325 [Last accessed 22 April 2014]
36. Erlotinib and gefitinib offer similar benefit in EGFR-mutated non-small cell lung cancer. Available from: http://www. ascopost.com/ViewNews.aspx?nid=15056 [Last accessed 22 April 2014]
37. A study to evaluate the efficacy of bevacizumab in combination with tarceva for advanced non-small cell lung cancer. Available from: http://clinicaltrials.gov/ show/NCT00130728 [Last accessed 22 April 2014]
38. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
39. Ross HJ, Blumenschein GR, Aisner J, et al. Randomized phase II multicenter trial of two schedules of lapatinib as firstor second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 2010;16:1938-49
40. Spector NL, Xia W, Burris H III, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12
41. Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010;15:924-34
42. Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009;31:2332-48
43. Tan F, Shen X, Wang D, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 2012;76:177-82
44. Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013;14:953-61
45. Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013;19:1389-400
46. Su K-Y, Chen H-Y, Li K-C, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012;30:433-40
47. Bean J, Riely GJ, Balak M, et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008;14:7519-25
48. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012;13:23-31
49. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501
50. Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007;4:1669-79. Discussion 80
51. Takezawa K, Pirazzoli V, Arcila ME, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012;2:922-33
52. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:57-61
53. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43
54. Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 2012;109:E2127-33
55. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-smallcell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65:9455-62
56. Uramoto H, Iwata T, Onitsuka T, et al. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 2010;30:2513-17
57. Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012;18:521-8
58. Pao W, Miller V, Politi K, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73
59. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92
60. Yun C-H, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-5
61. Fry DW, Bridges AJ, Denny WA, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and ErbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998;95:12022-7
62. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-50
63. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-38
64. Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013;31:3335-41
65. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34
66. Afatinib. Available from: http://www.fda. gov/Drugs/InformationOnDrugs/ ApprovedDrugs/ucm360574.htm [Last accessed 11 March 2014]
67. Wu YL, Zhou C, Hu C-P, et al. LUX-Lung 6: A randomized, openlabeled, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as firstline treatment for Asian patients with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol 2013;31: abstract 8016
68. Kohler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie 2013;36:510-18
69. Nelson V, Ziehr J, Agulnik M, et al. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Oncol Targets Ther 2013;6:135-43
70. Brzezniak C, Carter CA, Giaccone G. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin Pharmacother 2013;14:247-53
71. Takahashi T, Boku N, Murakami H, et al. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1,-2, and-4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs 2012;30:2352-63
72. Janne PA, Schellens JH, Engelman JA, et al. Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. J Clin Oncol 2008;26:abstract 8027
73. Campbell A, Reckamp KL, Camidge DR, et al. PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): a phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). J Clin Oncol 2010;28:7596
74. Park K, Heo DS, Cho B, et al. PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study. J Clin Oncol 2010;28:abstract 7599
75. Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3337-44
76. Kris MG, Mok T, Ou S-HI, et al. First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFRmutant lung cancers. J Clin Oncol 2012;30:abstract 7530
77. Kris MG, Camidge DR, Giaccone G, et al. Results with dacomotinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, in a phase II cohort of patients with HER2-mutant or amplified lung cancers. J Thorac Oncol 2013;8(Suppl 2):abstract P1.11-032
78. Pfizer announces top-line results from two phase 3 trials of dacomitinib in patients with refractory advanced nonsmall cell lung cancer. 2014.Available from: http://www.pfizer. com/news/press-release/press-releasedetail/ pfizer-announces-top-line- results-from-two-phase-3-trials- of-dacomitinib-in-patients-with- refractory-advanced-non-small-cell- lung-cancer [Last accessed 21 Febuary 2014]
79. Yu HA, Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw 2013;11:161-9
80. Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3076-83
81. Lai CJ, Bao R, Tao X, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 2010;70:3647-56
82. Soria J-C, Baselga J, Hanna N, et al. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and-4 and VEGFR-1 to-3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Eur J Cancer 2013;49:1815-24
83. Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog 2013;12:1-29
84. Zhou W, Ercan D, Jänne PA, et al. Discovery of selective irreversible inhibitors for EGFR-T790M. Bioorg Med Chem Lett 2011;21:638-43
85. Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-4
86. Walter AO, Tjin R, Haringsma H, et al. CO-1686, a novel mutant-selective EGFR inhibitor, overcomes T790Mmediated resistance in non-small cell lung cancer (NSCLC). Cancer Res 2012;72:abstract 1791
87. Walter AO, Sjin RTT, Haringsma HJ, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 2013;3:1404-15
88. Sequist LV, Soria J-C, Gadgeel SM, et al. First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. J Clin Oncol 2013;31:abstract 2524
89. Ranson M, Pao W, Kim D, et al. AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFRm+) and resistance (T790M) mutations in advanced NSCLC. J Thorac Oncol 2013;8(Suppl 2):abstract MO21.12
90. Berardi R, Santoni M, Morgese F, et al. Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. Onco Targets Ther 2013;6:563-76
91. Kim D-W, Kim S-W, Kim TM, et al. Phase I study of HM61713, a novel epidermal growth factor receptor (EGFR) mutant selective inhibitor, in non-small cell lung cancer (NSCLC) petients having an activating EGFR mutation but failed to prior EGFR tyrosine kinase inhibitor (TKI) therapy. J Thorac Oncol 2013;8(Suppl 2):abstract P2.11-010
92. Utsugi T. New challenges and inspired answers for anticancer drug discovery and development. Jpn J Clin Oncol 2013;43:945-53
93. Miyadera K, Kato M, Takahashi I, et al. TAS-2913 is a mutant selective EGFR inhibitor for NSCLC: characterization against EGFR T790M in cell and xenograft models. Eur J Cancer 2012;48:44
94. BetaPharma Pipeline. Available from: http://www.betapharma.com/index.html [Last accessed 26 December 2013]
95. Pietanza MC, Lynch TJ Jr, Lara PN Jr, et al. XL647-a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol 2012;7:219-26
96. Miknis G, Wallace E, Lyssikatos J, et al. ARRY-334543, A potent, orally active small molecule inhibitor of EGFR and ErbB-2. Cancer Res 2005;46:abstract 3399
97. Wong TW, Lee FY, Yu C, et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 2006;12:6186-93
98. Konings IR, de Jonge MJ, Burger H, et al. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br J Cancer 2010;103:987-92
99. Doi T, Takiuchi H, Ohtsu A, et al. Phase I first-in-human study of TAK-285, a novel investigational dual HER2/ EGFR inhibitor, in cancer patients. Br J Cancer 2012;106:666-72
100. Advenchen Laboratory Drug Development Pipeline. Advenchen Laboratory. 2013.Available from: http://www. advenchen.com/pipeline.html [Last accessed 24 December 2013]
101. Klebl B, Muller G, Hamacher M, et al. Protein kinases as drug targets. Wiley-VCH; 2011
102. Norman P. Kinase therapeutics: pipeline assessment and commercial prospects. Cambridge Healthcare Institute; Cambridge: 2010
103. Baselga J, Mita AC, Schoffski P, et al. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788. Clin Cancer Res 2012;18:6364-72
104. Subramaniam DS, Hwang J. BIBW 2992 in non-small cell lung cancer. Expert Opin Investig Drugs 2011;20:415-22
105. Carpenter RL, Lo HW. Dacomitinib, an emerging HER-targeted therapy for nonsmall cell lung cancer. J Thorac Dis 2012;4:639-42
106. Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-65
107. Cha MY, Lee KO, Kim M, et al. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer 2012;130:2445-54
108. Nam HJ, Kim HP, Yoon YK, et al. Antitumor activity of HM781-36B, an irreversible pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett 2011;302:155-65
109. Wong TW, Lee FY, Emanuel S, et al. Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families. Clin Cancer Res 2011;17:4031-41
110. Marathe P, Tang Y, Sleczka B, et al. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci 2010;99:3579-93
111. Lai C-J, Bao R, Tao X, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 2010;70:3647-56
112. Wang J, Pursell NW, Samson MES, et al. Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. Mol Cancer Ther 2013;12:925-36
113. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102:7665-70
114. Suzuki T, Fujii A, Ohya J, et al. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. Cancer Sci 2007;98:1977-84
115. Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001;28:80-5
116. Yoshimura N, Kudoh S, Kimura T, et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006;51:363-8
117. Ballard P, Ashton S, Cross D, et al. Integrating the preclinical pharmacokinetic, pharmacodynamics, and efficacy data for AZD9291, an oral, irreversible inhibitor of EGFR activating and resistant mutation. Mol Cancer Ther 2013;12:abstract B212